Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Myosin light chain 6B (MYL6B) is a myosin alkali light chain protein expressed in both slow-twitch skeletal muscle and nonmuscle tissues and is a structural component of the myosin hexameric ATPase motor complex, where it regulates cytoskeletal organization and actin/microtubule dynamics as part of cellular motility processes. It does not bind calcium but helps modulate myosin ATPase activity and fine-tunes muscle contraction and cell structure maintenance. MYL6B is implicated in broader cellular processes through interactions with signaling proteins, and recent studies suggest roles in cancer progression (notably by promoting MDM2-mediated p53 degradation in hepatocellular carcinoma), but it is not currently established as a direct therapeutic target.
null (not a known direct pharmacological target; possible indirect modulation via cytoskeletal or cancer pathways, e.g., modulation of p53 degradation in cancer)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Myosin light chain 6B (MYL6B).